Vanguard Capital Wealth Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Vanguard Capital Wealth Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,485	Closed	-$393K	–	154
2024 Q2	$393K	Buy	2,485 +35	+1%	+$4.5K	0.27%	81
2024 Q1	$317K	Hold	2,450	–	–	0.22%	90
2023 Q4	$236K	Buy	2,450 +90	+4%	+$8.63K	0.19%	110
2023 Q3	$286K	Buy	2,360 +10	+0.4%	+$1.13K	0.27%	79
2023 Q2	$269K	Hold	2,350	–	–	0.24%	89
2023 Q1	$324K	Hold	2,350	–	–	0.32%	70
2022 Q4	$305K	Hold	2,350	–	–	0.35%	70
2022 Q3	$260K	Buy	+2,350	New	+$237K	0.32%	77
2022 Q1	–	Sell	-2,400	Closed	-$216K	–	167
2021 Q4	$216K	Hold	2,400	–	–	0.16%	125
2021 Q3	$222	Buy	+2,400	New	+$185K	0.15%	128
2021 Q1	–	Sell	-4,250	Closed	-$729K	–	161
2020 Q4	$729K	Buy	+4,250	New	+$630K	0.67%	38
2020 Q2	$729K	Buy	+4,550	New	+$619K	0.85%	33
2019 Q4	$625K	Buy	4,850 +650	+15%	+$65.6K	0.65%	41
2019 Q3	$316K	Sell	4,200 -500	-11%	-$59K	0.37%	81
2019 Q2	$714K	Hold	4,700	–	–	0.86%	35
2019 Q1	$560K	Hold	4,700	–	–	0.7%	44
2018 Q4	$512K	Sell	4,700 -200	-4%	-$25K	0.76%	43
2018 Q3	$791K	Hold	4,900	–	–	0.9%	28
2018 Q2	$647K	Sell	4,900 -100	-2%	-$9.43K	0.86%	43
2018 Q1	$359K	Sell	5,000 -300	-6%	-$20K	0.47%	64
2017 Q4	$295K	Buy	+5,300	New	+$281K	0.37%	80

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Vanguard Capital Wealth Advisors's SRPT Position: Q3 2024 in Review

Vanguard Capital Wealth Advisors sold out of Sarepta Therapeutics (SRPT) in Q3 2024, closing a stake of 2,485 shares — an estimated $393K sold.

Vanguard Capital Wealth Advisors first reported a position in SRPT in Q4 2017 and held it in 21 quarters. The position peaked at $791K in Q3 2018. 457 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

Vanguard Capital Wealth Advisors reported no remaining Sarepta Therapeutics position as of Q3 2024 after selling out during the quarter.
Vanguard Capital Wealth Advisors sold 2,485 Sarepta Therapeutics shares in Q3 2024, an estimated $393K.
Vanguard Capital Wealth Advisors first reported a position in Sarepta Therapeutics in Q4 2017 and held it in 21 quarters.
Vanguard Capital Wealth Advisors's Sarepta Therapeutics position peaked at $791K in Q3 2018.
457 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on Vanguard Capital Wealth Advisors's 13F filing for Q3 2024, filed 25 Oct 2024.